[go: up one dir, main page]

WO1997030148A1 - Conjugaison de polypeptides - Google Patents

Conjugaison de polypeptides Download PDF

Info

Publication number
WO1997030148A1
WO1997030148A1 PCT/DK1997/000051 DK9700051W WO9730148A1 WO 1997030148 A1 WO1997030148 A1 WO 1997030148A1 DK 9700051 W DK9700051 W DK 9700051W WO 9730148 A1 WO9730148 A1 WO 9730148A1
Authority
WO
WIPO (PCT)
Prior art keywords
molecules
polypeptide
kda
polymeric carrier
carrier molecule
Prior art date
Application number
PCT/DK1997/000051
Other languages
English (en)
Inventor
Henrik Bisgård-Frantzen
Arne Agerlin Olsen
Annette PRENTØ
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Priority to EP97901524A priority Critical patent/EP0894128A1/fr
Priority to JP9528900A priority patent/JP2000506119A/ja
Priority to AU15406/97A priority patent/AU725287B2/en
Publication of WO1997030148A1 publication Critical patent/WO1997030148A1/fr
Priority to US09/123,787 priority patent/US6106828A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q9/00—Preparations for removing hair or for aiding hair removal
    • A61Q9/02—Shaving preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/88—Polyamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/10—Preparations for permanently dyeing the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/12—Preparations containing hair conditioners
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/384—Animal products
    • C11D3/3845—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16—Organic compounds
    • C11D3/38—Products with no well-defined composition, e.g. natural products
    • C11D3/386—Preparations containing enzymes, e.g. protease or amylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/082—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • C12N11/087—Acrylic polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/10—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a carbohydrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances

Definitions

  • the present invention relates to a polypeptide conjugate with reduced allergenicity, a process for producing said polypeptide conjugate with reduced allergenicity, compositions comprising said polypeptide conjugate with reduced allergenicity, the use of said polypeptide conjugate for reducing the allerginicity of a vast number of industrial products and the use in a number of 0 applications, such as the use in personal care products and in detergent compositions.
  • polypeptides including proteins and 5 enzymes, such as proteases
  • Said polypeptides may under certain circumstances inflict a potential risk to especially employees handling the manufacturing of products containing polypeptides, 0 and also to some extent to users of these products, such as hairdressers, and end-users of cosmetic and toiletry products etc.
  • polypeptides are potential antigens toward which the human immune system can produce specific antibodies upon expo ⁇ sure. This process is known as "immunization” when a clinical 0 beneficial response is obtained whereas the term “sensitiza- tion” is applied when the response leads to hypersensitivity.
  • the allergic reaction can be defined as an pathological immune response elicited by otherwise un- harmful agents in low concentrations.
  • the process of sensitisa- tion leading to type I hypersensitivity are characterized by the formation of specific IgE antibodies. At present, the me- chanism controlling the subclass shifting are not fully under ⁇ stood.
  • IgE secreted from activated B-cells can attach to Fc ⁇ receptors located on the surface of mast cells and basophil granulocytes, which contain numerous cytoplasmic granules packed with chemi ⁇ cal mediators e . g. histamine (J. Klein, "Immunology", Blackwell Sci. Pub., London, 1990; E. Benjamini & S. Leskowitz, "Immuno ⁇ logy", iley-Liss, N.Y. 1991).
  • each of these cells can have a high num ⁇ ber of IgE molecules bound to its surface, where they can re ⁇ main available to interact with allergens for weeks.
  • the surface bound IgE crossbinds the al ⁇ lergen, leading to the release of cytoplasmic granules into the proximity of the cell, thereby causing the inflammatoric aller ⁇ gic reaction.
  • IgE The role of IgE has been shown to relate to natural immunologic defence systems towards parasitic worms infections and the de- velopment of allergies has been suggested to be an unfortunate by-product of this defence system.
  • the natural allergens causing IgE mediated hypersensitivity can be classified according to their way of exposure: Inhalant allergens (pollens, dust mites etc.), Ingested allergens (milk, eggs etc.); Contact allergens (e.g. from latex) and allergens from stinging insects (e.g. bees, fire ants etc.).
  • Inhalant allergens polylens, dust mites etc.
  • Ingested allergens milk, eggs etc.
  • Contact allergens e.g. from latex
  • allergens from stinging insects e.g. bees, fire ants etc.
  • the aero-al ⁇ lergens represents clinically by far the largest group, stressing an area of high potential risk for the industrial polypeptides.
  • Testing for allergy can either be performed as in vivo provoca ⁇ tion, most commonly skin prick testing of by a number of in vi- tro assays, primarily based on IgE levels in pheriperal blood. In spite of the great efforts in the latter area the most re ⁇ liable way to diagnose allergy is still the in vivo challeng ⁇ ing, which again has different levels of sensitivity depending on the selected target organ.
  • intranasal challenge with allergenic proteins can provoke an allergic response even though skin tests and radio- allergosorbent test (RAST) for specific serum IgE are negative (Ivan Roitt, "Essential Immunology", fifth edition, p. 152 and p. 240, 1984).
  • RAST radio- allergosorbent test
  • PEGylation Another technology which can be used for reducing the immune system's response towards polypeptides is the "PEGylation"- technology, which involves modification of polypeptides by means of covalent attachment of strands of polyethylene glycol (PEG) , to polypeptide molecules.
  • PEG polyethylene glycol
  • Figure 1 shows the number of Dunkin Hartley guinea pig having been exposed to 1.0 ⁇ g monomer Peroxidase and 1.0 ⁇ g Dextran- Peroxidase A and B intratracheally found to be enzyme specific positive vs. weeks starting from the day of exposure.
  • Figure 2 shows the number of Dunkin Hartley guinea pig having been exposed to 1.0 ⁇ g lipase and 1.0 ⁇ g Dextran-lipase intratracheally found to be enzyme specific positive vs. weeks starting from the day of exposure.
  • Figure 3 shows the number of Dunkin Hartley guinea pig having been exposed to 1.0 ⁇ g cellulase and 1.0 ⁇ g Dextran-cellulase intratracheally found to be enzyme specific positive vs. weeks starting from the day of exposure.
  • Immunogenicity is a wider term than “antigenicity” and “al ⁇ lergenicity” and expresses the immune systems response to the presence of foreign substances. Said foreign substances are called “immunogens”, “antigens” and “allergens”, respectively, depending on the type of immune response they elicit.
  • an “immunogen” is a substance which, when introduced into cir ⁇ culatory system of animals and humans, is capable of stimulat ⁇ ing an immunologic response.
  • antigen refers to substances which by themselves are capable of generating antibodies when recognized as a non-self molecule.
  • An "allergen” is an antigen which gives rise to allergic sen- sitization or an allergic response due to the formation of IgE antibodies (in humans, and molecules with comparable effects in animals) .
  • the above used term "circulatory system" of the body of humans and animals means in the context of the present invention the system which mainly consist of the heart and blood vessels.
  • the heart delivers the necessary energy for maintaining blood circulation in the vascular system.
  • the circulation system functions as the organisms transportation system, transporting (in the blood) 0 2 , nutritious matter, hormones, and other substances of importance for the cell regulation into the tissue.
  • the blood removes C0 2 from the tissue to the lungs and residual substances to e .g. the kidneys.
  • the blood is of importance for the temperature regulation and the defence mechanisms of the body, including the immune system.
  • a polypeptide conjugate having "reduced allergenicity” indicates that the amount of produced IgE (in humans, and molecules with comparable effects in specific animals) , which might lead to an allergic state, is significantly decreased when inhaling a polypeptide conjugate of the invention in comparison to the corresponding parent po ⁇ lypeptide molecule.
  • assessment of allergenicity may be made by inhala- tion tests, comparing the effect of intratracheal administrated parent polypeptides with the corresponding polypeptides of the invention with reduced allergenicity.
  • a suitable strain of guinea pigs does not as humans, produce IgE antibodies as the allergic response. However, they produce another type of antibody the IgGlA and IgGIB (see e . g. Prent ⁇ , ATLA, 19, p. 8-14, 1991), which are responsible for their allergenic response to inhaled polypeptides including enzymes. Therefore, when using the Dun- kin Hartley animal model, the relative amount of IgGlA and IgGIB is a measure of the allergenicity level.
  • a rat strain suitable for intratracheal exposure to polypep ⁇ tides and enzymes is the Brown Norway strain.
  • the Brown Norway strain produces IgE as the allergic response.
  • Example 1 the surprising discovery of the present invention is disclosed showing that the allergenicity of purified wild- type Coprinus cinerea peroxidase coupled to dextran (M r about 1,000 kDa) intratrachaelly introduced into Dunkin Hartley guinea pigs is reduced in comparison to the corresponding monomer peroxidase (M r about 39 kDa) .
  • Example 2 and 3 show that also the allergenicity of lipase and cellulase, respectively is reduced.
  • the invention relates to a polypeptide conjugate with reduced allergenicity which comprises one polymeric carrier molecule having two or more polypeptide molecules coupled covalently thereto.
  • polypeptide molecules may be coupled to the polymeric carrier molecule using any methods. It is well-known by a person skilled in the art to couple chemical groups on the polypeptides, such as free hydrolxy groups, free sulfhydryl groups, free acid groups, free amino groups, to hydroxy groups of a vast number of polymeric (carrier) molecule.
  • the polymeric carrier mole ⁇ cule is coupled with two or more polypeptide molecules via a covalent linkage formed between one of the two vinyl groups of a divinyl sulfone.
  • polypeptides means in the context of the present in ⁇ vention all types of polypeptides such as proteins, enzymes, ligands, antibodies, inhibitors, receptors which may constitute a greater or less part of a commercial product.
  • polypeptides which, as ingredients in a commer- cial product, are not to be introduced into the circulatory sy ⁇ stem of the body of humans or animals.
  • the invention relates to a process for producing polypeptides with reduced allergenicity comprising the steps of i) activating a polymeric carrier molecule, and ii) reacting two or more polypeptide molecules with said activated polymeric carrier molecule under conditions suitable for conjugation, and iii) blocking of residual active groups on the conjugate.
  • the polymeric carrier molecule is coupled directly with two or more polypeptide molecules or via a reactive linker molecule.
  • step i) The activation of the polymeric carrier molecule in step i) may be performed by any method known in the art. Examples of such suitable coupling methods will be described below.
  • two or more polypeptide molecules are coupled to the polymeric carrier molecule via a divinyl sulfone.
  • the third object of the invention is to provide compositions comprising a polypeptide conjugate of the invention.
  • compositions may further comprise polypeptides, such as proteins and/or enzymes and/or ingredients normally used in e.g. products such as detergents, household article products, agrochemicals, personal care products, cosmetics, toiletries, oral-, skin and hair care products, composition use for pro- cessing textiles, compositions for cleaning hard surfaces, compositions used for manufacturing food, feed, juice, wine and beverages, and also oral and dermal pharmaceuticals.
  • polypeptides such as proteins and/or enzymes and/or ingredients normally used in e.g. products such as detergents, household article products, agrochemicals, personal care products, cosmetics, toiletries, oral-, skin and hair care products, composition use for pro- cessing textiles, compositions for cleaning hard surfaces, compositions used for manufacturing food, feed, juice, wine and beverages, and also oral and dermal pharmaceuticals.
  • the invention relates to the use of poly- peptide conjugates of the invention for a number of applica ⁇ tions for industrial products, such as personal care applica ⁇ tions and the use in detergent compositions.
  • polypeptide con ⁇ jugates with reduced allergenicity.
  • conjugate one or more polymeric molecules to one polypeptide carrier molecule by covalently attaching one or more of poly- meric molecules to e .g. the amino-groups of a polypeptide car ⁇ rier molecule.
  • polypeptide con ⁇ jugates e . g. enzyme conjugates
  • the activity e.g. catalytic activity
  • polypeptide con ⁇ jugates e . g. enzyme conjugates
  • steric hindrance i.e. low accessibility of the substrate to the active site of the polypeptide molecule, e.g. enzyme
  • the inventors have found that conjugation techniques resulting in the coupling of two or more polypeptide molecule to each polymeric carrier molecule reduces the allergenicity of polypeptide molecules suitable for industrial products.
  • polypeptide conjugates are also more stable than corres ⁇ ponding parent polypeptide molecules.
  • Polypeptide conjugates according to the present invention may also have advantages in comparison to polypeptide conjugates having several polymeric molecules attached to each polypeptide carrier molecules, as - the amount of excess polypeptide molecules needed for the conjugation process is less than the amount needed for corre ⁇ sponding prior art processes conjugating several polymeric molecules to each polypeptide carrier molecule, as only one attachment-group on the polypeptide molecule is needed.
  • polypeptide con ⁇ jugates of the invention is maintained to a greater extend than corresponding prior art polypeptide conjugates having several polymeric molecules attached to each polypeptide carrier mole ⁇ cules, as the steric hindrance is less.
  • the invention relates to poly- peptide conjugates with reduced allergenicity which comprise one polymeric carrier molecule having two or more polypeptide molecules coupled covalently thereto.
  • the two or more polypeptide molecules may be coupled to the polymeric carrier molecule by any method known in the art.
  • said conjugate comprises a polymeric carrier molecule having coupled thereto, via a cova ⁇ lent linkage, formed between one of the two vinyl groups of a divinyl sulfone, one or more polypeptide molecules.
  • the total molecular weight (M r ) of said polypeptide conjugate lies in the range between 50 kDa and 40,000 kDa, preferably be ⁇ tween 100 kDa and 1000, especially 200 kDa and 500 kDa.
  • conjugates according to the invention have between 1 and 60, preferably 2 and 40, especially 3 and 20 polypeptide molecules coupled to each polymeric carrier molecule.
  • polypeptide molecules may exhibit different activi- ties, such as two different enzyme activities. Further, said polypeptide molecules may also be functionally different.
  • Examples of functionally different polypeptide molecules include enzyme molecules, ligand molecules, inhibitor mol ⁇ ecules, receptor molecules and antibody molecules.
  • conjugates having coupled thereto e.g. an enzyme, such as an oxidase and an effector molecule (i.e. an enhancer). Due to the proximity of said two molecules a very effective conjugate can be obtained.
  • an enzyme such as an oxidase and an effector molecule (i.e. an enhancer). Due to the proximity of said two molecules a very effective conjugate can be obtained.
  • the polymeric carrier molecule to which the polypeptide ole- cules are to be coupled may be any polymer with more than two attachment groups.
  • the synthetic homo- and heteropolymeric carrier molecules in ⁇ clude Star-PEGs, Branched PEGs, poly-vinyl alcohol (PVA) , poly ⁇ carboxylates, poly-(vinylpyrolidone) and poly-D,L-amino acids.
  • Star-PEGs are multi-armed polyethylene glycol molecules made by polymerization of ethylene oxide molecules from a crosslinked divinyl benzene core (Gnanou et al. (1988), Makromol. Chem. 198, 2885; Rein et al (1993), Acta Polymer, 44, 225) .
  • Star-PEGs and also Branched PEGs are available from Shearwater Inc., USA) .
  • suitable naturally occurring homo- and heteropoly ⁇ mers comprise dextrans including carboxymethyl-dextrans, cellu- loses such as methylcellulose, carboxymethylcellulose, ethyl- cellulose, hydroxyethylcellulose and hydroxypropylcellulose, hydrolysates of chitosan, starches, such as hydroxyethyl- starches and hydroxypropyl-starches, glycogen, agarose, guar gum, inulin, pullulan, xanthan gum, carrageenin, pectin, alginic acid etc.
  • the molecular weight of the polymeric carrier molecule lies between 1 kDa and 10,000 kDa, preferably between 2 kDa and 5,000 kDa, especially between 5 kDa and 500 kDa.
  • polypeptide molecule The polypeptide molecule
  • polypeptide molecules to be coupled to the polymeric carrier molecule may be any type of polypeptide molecules. However, it is preferred that said polypeptide molecule have some sort of functionality.
  • the polypeptide to be modified according to the invention may be of plant, animal or microbial origin, although the polypep ⁇ tide molecules of microbial origin, such as of bacterial or fungal origin (i.e. originated from filamentous fungi or yeasts) are preferred.
  • polypeptide molecules are proteins having either an anti-microbial, biological or enzymatic activity.
  • the protein being an enzyme it may be an enzyme from the group including hydrolases, such as proteases, lipases and cellulase, transferases, carbohydrases, oxidoreductases, such as laccase and peroxidase, or phytases.
  • hydrolases such as proteases, lipases and cellulase, transferases, carbohydrases, oxidoreductases, such as laccase and peroxidase, or phytases.
  • enzymes used in industrial products have a molecular weight in the range from about 4 kDa to 200 kDa, preferably 15 kDa to 150 kDa, especially 20 to 100 kDa.
  • Ligands contemplated according to the invention will in most case have a molecular weight in the range from 100 dalton to 2,000 dalton.
  • the inventors have found that the enzymatic activity of enzyme conjugates of the invention are substantially maintained.
  • a “substantially” maintained activity is in the context of the present invention defined as an activity which is at least be- tween 20% and 30%, preferably between 30% and 40%, more pre ⁇ ferably between 40% and 60%, better from 60% up to 80%, even better from 80% up to about 100%, in comparison to the activity of the parent unmodified polypeptide molecule.
  • the invention relates to a process which is suitable for large scale processing of polypeptide molecules to obtain polypeptide conjugates with reduced allergenicity.
  • one or more polypeptide molecules are coupled to each polymeric carrier molecule by i) activating said polymeric carrier molecule, and ii) reacting one or more polypeptide molecules with said activated polymeric carrier molecule under conditions suitable for obtaining conjugation, and iii) blocking of residual active groups on the conjugate.
  • step i) The activation of the polymeric carrier molecule in step i) may be performed by any method known in the art. Examples of such methods are described in the following.
  • the functional groups being amino, hydroxyl, thiol, carboxyl, aldehyde or sulfydryl on the polymeric mole ⁇ cule and the chosen attachment group(s) on the polypeptide molecule(s) must be considered when choosing the activation and conjugation chemistry.
  • Organic sulfonyl chlorides e.g. Tresyl chloride
  • Tresyl chloride effectively converts hydroxy groups in a number of polymeric molecules into good leaving groups (sulfonates) that, when reacted with nu- cleophiles, like amino groups in the polypeptide chain, allow stable linkages to be formed between the polymeric molecule and the polypeptide molecules.
  • the reaction conditions are in general mild (neutral or slightly alkaline pH, to avoid denaturation and little or no disruption of activity) , and satisfy the non-destructive requirements of the polypeptide molecules.
  • Oxirane groups and other epoxide groups may also been used for creating amine bonds.
  • Converting a polymeric carrier molecule, such as a polyol, into a chloroformate with phosgene gives rise to carbamate linkages to lysin groups in the polypeptide chain.
  • This theme can be played in many variants substituting the chlorine with N-hydro- xy succinimide, imidazole, para-nitrophenol, DMAP.
  • the deriva- tives are usually made by reacting the chloroformate with the desired leaving group. All these groups give rise to carbamate linkages to the polypeptide.
  • isocyanates and isothiocyanates may be employed yielding ureas and thioureas, respectively.
  • Amides may be obtained from polyol acids using the same leaving groups as mentioned above and cyclic imid thrones.
  • Polyol succinate made from reaction with succinic anhydride can also be used.
  • the hereby comprised ester group make the conju ⁇ gate much more susceptible to hydrolysis. This group may be activated with N-hydroxy succinimide.
  • Coupling to the polymeric carrier molecule of aromatic amine followed by diazotation yields a very reactive diazonium salt which in situ can be reacted with polypeptide molecules.
  • An amide linkage may also be obtained by reacting an azlactone derivative of polyols thus introducing an additional amide linkage.
  • Amino-groups of the polypeptide molecules may also be attached to polyols with carbamate linkages. Lysine residues may be used as the backbone.
  • two or more polypeptide molecules are coupled to each polymeric carrier molecules by a) activating said polymeric carrier molecule by coupling thereto a reactive moiety, and b) reacting two or more polypeptide molecules with said activated polymeric carrier molecule.
  • the activation in step a) is performed by covalently linking thereto a reactive moiety derived from divinyl sulfone.
  • compositions comprising a poly ⁇ peptide conjugate of the invention.
  • compositions may further comprise polypeptides, such as proteins and/or enzymes and/or ingredients normally used in e.g. detergents, including soap bars, household articles, agro- chemicals, personal care products, such as cleaning prepara ⁇ tions e . g . for contact lenses, cosmetics, toiletries, oral and dermal pharmaceuticals, composition use for treating textiles, compositions for cleaning hard surfaces, compositions used for manufacturing food, e.g. baking, and feed etc.
  • polypeptides such as proteins and/or enzymes and/or ingredients normally used in e.g. detergents, including soap bars, household articles, agro- chemicals, personal care products, such as cleaning prepara ⁇ tions e . g . for contact lenses, cosmetics, toiletries, oral and dermal pharmaceuticals, composition use for treating textiles, compositions for cleaning hard surfaces, compositions used for manufacturing food, e.g. baking, and feed etc.
  • polypeptides being enzymes include proteases, li- pases, oxidoreductases, carbohydrases, transferases, such as transglutaminases, anti-microbial polypeptides, and phytases.
  • Polypeptide conjugates of the invention may typically be a component of a detergent composition, e.g., a laundry detergent composition or a dishwashing deter ⁇ gent composition. As such, it may be included in the detergent composition in the form of a non-dusting granulate, a stabili- zed liquid, or a protected enzyme.
  • Non-dusting granulates may be produced, e.g., as disclosed in US 4,106,991 and 4,661,452 (both to Novo Industri A/S) and may optionally be coated by methods known in the art.
  • waxy coating materials are poly(ethylene oxide) products (polyethylene glycol, PEG) with mean molecular weights of 1000 to 20000; ethoxylated nonylphenols having from 16 to 50 ethylene oxide units; ethoxylated fatty alcohols in which the alcohol contains from 12 to 20 carbon atoms and in which there are 15 to 80 ethylene oxide units; fatty alcohols; fatty acids; and mono- and di- and triglycerides of fatty acids.
  • PEG poly(ethylene oxide) products
  • ethoxylated nonylphenols having from 16 to 50 ethylene oxide units
  • ethoxylated fatty alcohols in which the alcohol contains from 12 to 20 carbon atoms and in which there are 15 to 80 ethylene oxide units
  • fatty alcohols fatty acids
  • mono- and di- and triglycerides of fatty acids are given in patent GB 1483591.
  • Liquid enzyme preparations may, for instance, be stabilized by adding a polyol such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric acid according to established methods.
  • a polyol such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric acid according to established methods.
  • Other enzyme stabilizers are well known in the art.
  • Protected enzymes may be prepared according to the method disclosed in EP 238,216.
  • the detergent composition of the invention may be in any convenient form, e.g. as powder, granules, paste or liquid.
  • a liquid detergent may be aqueous, typically containing up to 70% water and 0-30% organic solvent, or non-aqueous.
  • the detergent composition comprises one or more surfactants, each of which may be anionic, non-ionic, cationic, or ampho ⁇ teric (zwitterionic) .
  • the detergent will usually contain 0-50% of anionic surfactant such as linear alkylbenzenesulfonate (LAS) , alpha-olefinsulfonate (AOS) , alkyl sulfate (fatty alcohol sulfate) (AS) , alcohol ethoxysulfate (AEOS or AES) , secondary alkanesulfonates (SAS) , alpha-sulfo fatty acid methyl esters, alkyl- or alkenylsuccinic acid, or soap.
  • anionic surfactant such as linear alkylbenzenesulfonate (LAS) , alpha-olefinsulfonate (AOS) , alkyl sulfate (fatty alcohol sulfate) (AS) , alcohol ethoxysul
  • non-ionic surfactant such as alcohol ethoxyla ⁇ te (AEO or AE) , alcohol propoxylate, carboxylated alcohol ethoxylates, nonylphenol ethoxylate, alkylpolyglycoside, alkyldimethylamine oxide, ethoxylated fatty acid monoethanol ⁇ amide, fatty acid monoethanolamide, or polyhydroxy alkyl fatty acid amide (e.g. as described in WO 92/06154) .
  • non-ionic surfactant such as alcohol ethoxyla ⁇ te (AEO or AE) , alcohol propoxylate, carboxylated alcohol ethoxylates, nonylphenol ethoxylate, alkylpolyglycoside, alkyldimethylamine oxide, ethoxylated fatty acid monoethanol ⁇ amide, fatty acid monoethanolamide, or polyhydroxy alkyl fatty acid amide (e.g. as described in WO 92/06154) .
  • the detergent composition may additionally comprise one or more enzymes, such as amylases, pullulanase, e ⁇ terase, lipase, cuti ⁇ nase, protease, cellulase, peroxidase, or oxidase, e.g., lac- case, and anti-microbial polypeptides.
  • enzymes such as amylases, pullulanase, e ⁇ terase, lipase, cuti ⁇ nase, protease, cellulase, peroxidase, or oxidase, e.g., lac- case, and anti-microbial polypeptides.
  • enzymes such as amylases, pullulanase, e ⁇ terase, lipase, cuti ⁇ nase, protease, cellulase, peroxidase, or oxidase, e.g., lac- case, and anti-m
  • the detergent contains 1-65% of a detergent builder, but some dishwashing detergents may contain even up to 90% of a detergent builder, or complexing agent such as zeolite, diphosphate, triphosphate, phosphonate, citrate, nitrilotriace- tic acid (NTA) , ethylenediaminetetraacetic acid (EDTA) , diethylenetriaminepentaacetic acid (DTMPA) , alkyl- or alkenyl- succinic acid, soluble silicates or layered silicates (e.g. SKS-6 from Hoechst) .
  • zeolite diphosphate, triphosphate, phosphonate, citrate, nitrilotriace- tic acid (NTA) , ethylenediaminetetraacetic acid (EDTA) , diethylenetriaminepentaacetic acid (DTMPA) , alkyl- or alkenyl- succinic acid, soluble silicates or layered silicates (
  • the detergent builders may be subdivided into phosphorus- containing and non-phosphorous-containing types.
  • phosphorus-containing inorganic alkaline detergent builders include the water-soluble salts, especially alkali metal pyrophosphates, orthophosphates, polyphosphates and phospho ⁇ nates.
  • non-phosphorus-containing inorganic builders include water-soluble alkali metal carbonates, borates and silicates as well as layered disilicates and the various types of water-insoluble crystalline or amorphous alu ino silicates of which zeolites is the best known representative.
  • suitable organic builders include alkali metal, am ⁇ monium or substituted ammonium salts of succinates, malonates, fatty acid malonates, fatty acid sulphonates, carboxymethoxy succinates, polyacetates, carboxylates, polycarboxylates, ami- nopolycarboxylates and polyacetyl carboxylates.
  • the detergent may also be unbuilt, i.e. essentially free of detergent builder.
  • the detergent may comprise one or more polymers.
  • examples are carboxymethylcellulose (CMC) , poly(vinylpyrrolidone) (PVP) , po ⁇ lyethyleneglycol (PEG) , poly(vinyl alcohol) (PVA) , polycarboxy ⁇ lates such as polyacrylates, polymaleates, maleic/acrylic acid copolymers and lauryl methacrylate/acrylic acid copolymers.
  • CMC carboxymethylcellulose
  • PVP poly(vinylpyrrolidone)
  • PEG po ⁇ lyethyleneglycol
  • PVA poly(vinyl alcohol)
  • polycarboxy ⁇ lates such as polyacrylates, polymaleates, maleic/acrylic acid copolymers and lauryl methacrylate/acrylic acid copolymers.
  • the detergent composition may contain bleaching agents of the chlorine/bromine-type or the oxygen-type.
  • the bleaching agents may be coated or incapsulated.
  • inorganic chlor- ine/bromine-type bleaches are lithium, sodium or calcium hypo ⁇ chlorite or hypobromite as well as chlorinated trisodium phosphate.
  • the bleaching system may also comprise a H 2 0 2 source such as perborate or percarbonate which may be combined with a peracid-for ing bleach activator such as tetraacetylethylene- diamine (TAED) or nonanoyloxybenzenesulfonate (NOBS) .
  • TAED tetraacetylethylene- diamine
  • NOBS nonanoyloxybenzenesulfonate
  • organic chlorine/bromine-type bleaches are he ⁇ terocyclic N-bromo and N-chloro imides such as trichloro- isocyanuric, tribromoisocyanuric, dibro oisocyanuric and dichloroisocyanuric acids, and salts thereof with water solu ⁇ bilizing cations such as potassium and sodium.
  • Hydantoin com ⁇ pounds are also suitable.
  • the bleaching system may also com ⁇ prise peroxyacids of, e.g., the amide, i ide, or sulfone type.
  • oxygen bleaches are preferred, for example in the form of an inorganic persalt, preferably with a bleach precursor or as a peroxy acid compound.
  • suitable peroxy bleach compounds are alkali metal perborates, both tetrahydrates and monohydrates, alkali metal percarbonates, persilicates and perphosphates.
  • Preferred activator materials are TAED or NOBS.
  • the enzymes of the detergent composition of the invention may be stabilized using conventional stabilizing agents, e.g. a polyol such as propylene glycol or glycerol, a sugar or sugar alcohol, lactic acid, boric acid, or a boric acid derivative such as, e.g., an aromatic borate ester, and the composition may be formulated as described in, e.g., WO 92/19709 and WO 92/19708.
  • the enzymes of the invention may also be stabilized by adding reversible enzyme inhibitors, e.g., of the protein type as described in EP 0 544 777 BI.
  • the detergent may also contain other conventional detergent ingredients such as, e.g., fabric conditioners including clays, deflocculant material, foam boosters/foam depressors (in dishwashing detergents foam depressors) , suds suppressors, anti-corrosion agents, soil-suspending agents, anti-soil- redeposition agents, dyes, dehydrating agents, bactericides, optical brighteners, or perfume.
  • fabric conditioners including clays, deflocculant material, foam boosters/foam depressors (in dishwashing detergents foam depressors) , suds suppressors, anti-corrosion agents, soil-suspending agents, anti-soil- redeposition agents, dyes, dehydrating agents, bactericides, optical brighteners, or perfume.
  • the pH (measured in aqueous solution at use concentration) will usually be neutral or alkaline, e.g. in the range of 7-11.
  • laundry detergent compositions within the scope of the invention include: 1) A detergent composition formulated as a granulate having a bulk density of at least 600 g/1 comprising
  • Alcohol ethoxysulfate e.g. Ci2_ ⁇ alcohol, 1-2 EO
  • alkyl sulfate 1 - 4% e.g. C 16 _ 18
  • Alcohol ethoxylate e.g. C14.-15 alco ⁇ hol, 7 EO 5 - 9%
  • Soluble silicate (as Na2 ⁇ ,2Si0 2 ) 2 - 6%
  • Polymers e.g. maleic/acrylic acid copoiymer, PVP, PEG 0 - 3%
  • Enzymes including modified enzymes 0.0001 - 0.5% (calculated as pure enzyme protein)
  • Minor ingredients e.g. suds suppressors, perfume, optical 0 - 5% brightener, photobleach
  • a detergent composition formulated as a granulate having a bulk density of at least 600 g/1 comprising
  • Linear alkylbenzenesulfonate (cal ⁇ culated as acid) 6 - 11%
  • Alcohol ethoxysulfate e.g. C12-I8 alcohol, 1-2 EO or alkyl sulfate 1 - 3% (e.g. C 16 _ 18 )
  • Alcohol ethoxylate e.g. Ci4_ 5 alco ⁇ hol, 7 EO
  • Ci4_ 5 alco ⁇ hol, 7 EO 5 - 9%
  • Soluble silicate (as Na2 ⁇ ,2Si ⁇ 2) 1 - 4%
  • Polymers e.g. maleic/acrylic acid copoiymer, PVP, PEG 1 - 6%
  • Enzymes including modified enzymes 0.0001 - 0.5% (calculated as pure enzyme protein)
  • Minor ingredients e.g. suds 0 - 5% suppressors, perfume
  • a detergent composition formulated as a granulate having a bulk density of at least 600 g/1 comprising
  • Alcohol ethoxylate e.g. C 2 - 15 alco ⁇ hol, 7 EO
  • Soap as fatty acid e.g. C e_ 22 fatty 1 - 3% acid
  • Soluble silicate (as Na 2 ⁇ ,2Si0 2 ) 3 - 9%
  • Phosphonate e.g. EDTMPA 0 - 1%
  • Polymers e.g. maleic/acrylic acid copoiymer, PVP, PEG 0 - 3%
  • Enzymes including modified enzymes 0.0001 - 0.5% (calculated as pure enzyme protein)
  • Minor ingredients e.g. suds suppressors, perfume, optical 0 - 5% brightener
  • a detergent composition formulated as a granulate having a bulk density of at least 600 g/1 comprising
  • Alcohol ethoxylate e.g. C 12 - 15 alco ⁇ hol, 7 EO
  • Soluble silicate (as Na 2 0,2Si0 ) 1 - 5%
  • Polymers e.g. maleic/acrylic acid copoiymer, PVP, PEG 1 - 3%
  • Enzymes including modified enzymes 0.0001 - 0.5% (calculated as pure enzyme protein)
  • Minor ingredients e.g. suds 0 - 5% suppressors, perfume
  • An aqueous liquid detergent composition comprising
  • Linear alkylbenzenesulfonate (cal ⁇ 15 - 21% culated as acid)
  • Alcohol ethoxylate e.g. C 12 - 15 alco ⁇ hol, 7 EO or C 12 - 15 alcohol, 5 EO
  • Alkenylsuccinic acid (C 12 -. 14 ) 0 - 13%
  • Polymers e.g. PVP, PEG 0 - 3%
  • Enzymes including modified enzymes 0.0001 - 0.5% (calculated as pure enzyme protein)
  • Minor ingredients e.g. dispersants, suds suppressors, perfume, optical 0 - 5% brightener
  • An aqueous structured liquid detergent composition compris ⁇ ing
  • Alcohol ethoxylate e.g. C 2-15 alcohol, 7 EO, 3 - 9% or C 12 -i5 alcohol, 5 EO
  • Soap as fatty acid e.g. oleic 3 - 10% acid
  • Polymers e.g. PEG, PVP 0 - 3%
  • Anchoring polymers such as, e.g., lauryl ethacrylate/acrylic acid 0 - 3% copoiymer; molar ratio 25:1; MW 3800
  • Enzymes including modified enzymes 0.0001 - 0.5% (calculated as pure enzyme protein)
  • Minor ingredients e.g. dispersants, suds suppressors, per ⁇ 0 - 5% fume, optical brighteners
  • a detergent composition formulated as a granulate having a bulk density of at least 600 g/1 comprising
  • Soluble silicate (as Na 2 ⁇ ,2Si ⁇ 2 ) 1 - 4%
  • Polymers e.g. maleic/acrylic acid 1 - 5% copoiymer, PEG
  • Enzymes including modified enzymes 0.0001 - 0.5% (calculated as pure enzyme protein)
  • Minor ingredients e.g. optical brightener, suds suppressors, per ⁇ 0 - 5% fume
  • a detergent composition formulated as a granulate comprising
  • Soluble silicate (as Na2 ⁇ ,2Si ⁇ 2) 1 - 4%
  • Zeolite (as NaAlSi0 ) 30 - 50%
  • Polymers e . g. PVP, maleic/acrylic 1 - 5% acid copoiymer, PEG
  • Enzymes including modified enzymes 0.0001 - 0.5% (calculated as pure enzyme protein)
  • Minor ingredients e.g. suds 0 - 5% suppressors, perfume
  • a detergent composition formulated as a granulate comprising
  • Bleach activator e.g. NOBS or TAED 1 - 5%
  • Polymers e.g. polycarboxylate or 1 - 5% PEG
  • Enzymes including modified enzymes 0.0001 - 0.5% (calculated as pure enzyme protein)
  • An aqueous liquid detergent composition comprising
  • Alcohol ethoxysulfate e.g. C 2-1 5 alcohol, 2-3 EO 8 - 15%
  • Alcohol ethoxylate e.g. C 2-15 al ⁇ cohol, 7 EO, 3 - 9% or C12-15 alcohol, 5 EO
  • Soap as fatty acid e .g . lauric 0 - 3% acid
  • Hydrotrope e.g. sodium 2 - 6% toluensulfonate
  • Enzymes including modified enzymes 0.0001 - 0.5% (calculated as pure enzyme protein)
  • Minor ingredients e.g. polymers, dispersants, perfume, optical 0 - 5% brighteners
  • An aqueous liquid detergent composition comprising
  • Alcohol ethoxylate e.g. C 12 -i 5 alco ⁇ hol, 7 EO, 6 - 12% or C 12 - 15 alcohol, 5 EO
  • Polymer e.g. maleic/acrylic acid copoiymer, anchoring polymer such as, e.g., lauryl 0 - 3% methacrylate/acrylic acid copoiymer
  • Enzymes including modified enzymes 0.0001 - 0.5% (calculated as pure enzyme protein)
  • a detergent composition formulated as a granulate having a bulk density of at least 600 g/1 comprising
  • Anionic surfactant linear alkylbenzenesulfonate, alkyl sulfa ⁇ te, alpha-olefinsulfonate, alpha- 25 - 40% sulfo fatty acid methyl esters, alkanesulfonates, soap
  • Nonionic surfactant e.g. alcohol 1 - 10% ethoxylate
  • Soluble silicates (as Na 0, 2Si0 2 ) 5 - 15%
  • Enzymes including modified enzymes 0.0001 - 0.5% (calculated as pure enzyme protein)
  • a detergent composition formulated as a granulate having a bulk density of at least 600 g/1 comprising
  • Layered disilicate e.g. SK56 from Hoechst 10 - 20%
  • Soluble silicate (as Na2 ⁇ ,2Si0 2 ) 0 - 6%
  • Polymers e . g . polycarboxylates and 0 - 5% PVP
  • Enzymes including modified enzymes 0.0001 - 0.5% (calculated as pure enzyme protein)
  • a detergent composition formulated as a granulate having a bulk density of at least 600 g/1 comprising
  • Soluble silicate (as Na2 ⁇ ,2Si ⁇ 2) 0 - 4%
  • Polymers e.g. polycarboxylates and 0 - 3% PVP
  • Enzymes including modified enzymes 0.0001 - 0.5% (calculated as pure enzyme protein)
  • the manganese catalyst may, e.g., be one of the compounds described in "Efficient manganese catalysts for low-temperature bleaching", Nature, 369, (1994), p. 637-639.
  • Detergent composition formulated as a nonaqueous detergent liquid comprising a liquid nonionic surfactant such as, e.g., linear alkoxylated primary alcohol, a builder system (e.g.
  • the detergent may also comprise anionic surfactant and/or a bleach system.
  • dishwashing detergent compositions within the scope of the invention include:
  • Nonionic surfactant 0.4 - 2.5%
  • TED Tetraacetylethylenediamine
  • Nonionic surfactant 1 - 2% e.g. alcohol ethoxylate
  • NTA Nitrilotrisodium acetate
  • TED Tetraacetylethylenediamine
  • Polyacrylate polymer e.g. maleic acid/acrylic acid co- 6 - 25% polymer
  • Nonionic surfactant 0.5 - 2.0%
  • TED Tetraacetylethylenediamine
  • TED Tetraacetylethylenediamine
  • Liquid nonionic surfactant e.g. alcohol ethoxylates 2.0 - 10.0%
  • Liquid carrier selected from higher glycols, polyglycols, polyoxides, 25.0 - 45.0% glycolethers
  • Stabilizer e.g. a partial ester of phosphoric acid and a C 6 _ C 8 0.5 - 7.0% alkanol
  • Foam suppressor e.g. silicone 0 - 1.5%
  • Liquid nonionic surfactant e.g. alcohol ethoxylates 2.0 - 10.0%
  • Stabilizing system e.g. mixtures of finely divided silicone and low molecular weight dialkyl polyglycol 0.5 - 7.0% ethers
  • Clay gel thickener e.g. bentonite 0.0 - 10.0%
  • Liquid carrier selected from higher lycols, polyglycols, polyoxides and Balance glycol ethers
  • Oleic acid 0 - 10%
  • TED Tetraacetylethylenediamine
  • the manganese catalyst may, e.g., be one of the compounds described in "Effi- cient manganese catalysts for low-temperature bleaching", Na ⁇ ture, 369, (1994), p. 637-639.
  • Proteases are well-known active ingredients for cleaning of contact lenses. They hydrolyse the proteinaceous soil on the lens and thereby makes it soluble. Removal of the protein soil is essential for the wearing comfort.
  • Proteases are also effective ingredients in skin cleaning pro- ducts, where they remove the upper layer of dead keratinaseous skin cells and thereby make the skin look brighter and more fresh.
  • Proteases are also used in oral care products, especially for cleaning of dentures, but also in dentifrices.
  • proteases are used in toiletries, bath and shower products, including shampoos, conditioners, lotions, creams, soap bars, toilet soaps, and liquid soaps.
  • Lipases can be applied for cosmetic use as active ingredients in skin cleaning products and anti-acne products for removal of excessive skin lipids, and in bath and shower products such as creams and lotions as active ingredients for skin care.
  • Lipases can also be used in hair cleaning products (e.g. sham ⁇ poos) for effective removal of sebum and other fatty material from the surface of hair.
  • Lipases are also effective ingredients in products for cleaning of contact lenses, where they remove lipid deposits from the lens surface.
  • oxidase usually glucose oxidase
  • substrate e.g. glucose
  • SCN glucose oxidase
  • peroxidase usually lactoperoxidase
  • Anti-microbial systems comprising the combination of an oxidase and a peroxidase are known in the cleaning of contact lenses.
  • Oxidoreductases are oxidative hair dye ⁇ ing using oxidases, peroxidases and laccases.
  • the free radicals activate chain reactions that leads to destruction of fatty membranes, collagen, and cells.
  • free radical scavengers such as Superoxide dismutase into cosmetics is well-known (R. L. Goldemberg, DCI, Nov. 93, p. 48-52) .
  • Protein disulfide isomerase (PDI) is also an oxidoreductase. It can be utilised for waving of hair (reduction and reoxidation of disulfide bonds in hair) and repair of spoiled hair (where the damage is mainly reduction of existing disulfide bonds) .
  • Carbohydrases are also an oxidoreductase. It can be utilised for waving of hair (reduction and reoxidation of disulfide bonds in hair) and repair of spoiled hair (where the damage is mainly reduction of existing disulfide bonds) .
  • Plaque formed on the surface of teeth is composed mainly of polysaccharides. They stick to the surface of the teeth and the microorganisms.
  • the polysaccharides are mainly ⁇ -1, 6 bound glu ⁇ cose (dextran) and ⁇ -1,3 bound glucose (mutan) .
  • glucanases such as mutanase and dextra- nase helps hydrolysing the sticky matrix of plaque, making it easier to remove by mechanical action.
  • biofilm for instance the biofilm formed in lens cases can be removed by the action of glucanases.
  • Anti-microbial polypeptides have widespread applications such as for preservation of cosmetic products, anti-acne products, deodorants and shampoos. Further such polypeptides may be use in contact lens products.
  • Plasticizers Stearyl mono/diglycerides 0-10
  • Foam stabilizers Fatty acid alkanol amides 0.2-2 0-4
  • Active agents Vegetable extracts 0-1 0-1
  • Emulsifiers Sorbitane sesquioleate 3-5 Aluminum stearate 1-2 Triethanolamine stearate - 1-2 Cetyl/Stearyl alcohol polyglycol ethers 1-3
  • Body lotion oil-in-water type
  • skin lotion for application on the wet skin
  • Emulsifiers Cetyl/Stearyl alcohol polyglycol ethers 1 1 --33 — -
  • Foam boosters Fatty acid ethanol amides 0 . 5-2 . 5 Conditioners Quaternized hydroxyethyl 0 . 4-1 cellulose
  • Refatting agents Ethoxylated lanolin alcohols 0 . 2-1 Additives Anti-dandruff agents 0- 1 Preservatives 5-Bromo-5-nitro-l, 3-dioxane 0 . 1-0 . . 3 Pearlescent agents Ethyleneglycol stearate 0-2 Dyestuffs ⁇ 0.1 pH-Regulators Acids/Bases 0.1-1
  • Surfactants Fatty alcohol poly ⁇ glycol ethers 0.1-0.2 1.5-2.5 Cetyl trimethyl ammonium chloride 0.5-1 Dimethyl benzyl stearyl ammonium 0.5-1 chloride Refatting agents Cetyl/Stearyl mono/ diglyceride 0.5-1.5 1.5-2.5
  • Consistency regulators Fatty alcohols 1-2.5 2.5-3.5
  • Dyestuffs ⁇ 0.1 ⁇ 0.1 pH-Regulators Acids/Bases 0,1-1 0.1-1 Fragrances 0.2-0.5 0.2-0.5 Enzymes Protease/Lipase 0-5 0-5 Water Balance Balance Hair dyes
  • Component II Hydrogen peroxide dispersion Surfactants Lauryl ether sulfate 0.5-1 Oxidants Hydrogen peroxide 6-9 Stabilizers 1-Hydroxyethane-1, 1- diphos phonic acid 1-1.5
  • Emulsifiers Etboxylated castor oil 0 . . 1- -0 . . 5 Fragrances 0 . . 1- -0 . . 2 Dyestuffs ⁇ 0 . 1 Enzymes Lipase 0-5 Water Balance
  • conjugated enzymes or polypeptides with reduced aller- genicity may advantageously be used in the manufacturing of food and feed.
  • the gluten in wheat flour is the essential ingredient respon- sible for the ability of flour to be used in baked foodstuffs.
  • Proteolytic enzymes are sometimes needed to modify the gluten phase of the dough, e.g. a hard wheat flour can be softened with a protease.
  • Neutrase® is a commercially available neutral metallo protease that can be used to ensure a uniform dough quality and bread texture, and to improve flavour.
  • the gluten proteins are de ⁇ graded either moderately or more extensively to peptides, whereby close control is necessary in order to avoid excessive softening of the dough.
  • Proteases are also used for modifying milk protein.
  • proteases are used for brewing with unmalted cereals and for controlling the nitrogen content.
  • proteases are used so to speak to expand the animals digestion system.
  • lipase in the baking industry is rather new. Addition of lipase results in improved dough properties and an improved breadmaking quality in terms of larger volume, impro- ved crumb structure and whiter crumb colour.
  • the observed ef ⁇ fect can be explained by a mechanism where the lipase changes the interaction between gluten and some lipids fragment during dough mixing. This results in an improved gluten network.
  • lipases are used e.g. to minimize the amount of undesirable side-products, to modify fats by intereste ification, and to synthesis of esters.
  • oxidoreductases with reduced allergenicity may advantageously be used in the manufacturing of food and feed.
  • oxidoreductases are used for baking, glucose oxidase, lipoxygenase, peroxidase, catalase and combinations hereof.
  • bakers strengthen gluten by adding ascorbic acid and potassium bromate.
  • Some oxidoreductases can be used to re ⁇ place bromate in dough systems by oxidation of free sulfydryl units in gluten proteins. Hereby disulphide linkages are formed resulting in stronger, more elastic doughs with greater resis ⁇ tance.
  • GluzymeTM Novo Nordisk A/S
  • the dough strengthen is measured as greater resistance to mechan- ical shock, better oven spring and larger loaf volume.
  • Flour has varying content of amylases leading to differences in the baking quality. Addition of amylases can be necessary in order to standardize the flour. Amylases and pentosanases ge ⁇ nerally provide sugar for the yeast fermentation, improve the bread volume, retard retrogradation, and decrease the staling rate and stickiness that results from pentosan gums. Examples of carbohydrases are given below.
  • Certain maltogenic amylases can be used for prolonging the shelf life of bread for two or more days without causing gum- miness in the product.
  • the starch is modified in such a way that retrogradation is less likely to occur.
  • the produced low-molecular-weight sugars improve the baked goods water retention capacity without creating the in ⁇ termediate-length dextrins that result in gumminess in the finished product.
  • the enzyme is inactivated during bread baking, so it can be considered a processing aid which does not have to be declared on the label. The overdosing of Novamyl can almost be excluded.
  • the bread volume can be improved by fungal ⁇ -amylases which further provide good and uniform structure of the bread crumb.
  • Said ⁇ -amylases are endoenzymes that produce maltose, dextrins and glucose.
  • Cereal and some bacterial ⁇ -amylases are inacti ⁇ vated at temperatures above the gelatinization temperature of starch, therefore when added to a wheat dough it results in a low bread volume and a sticky bread interior.
  • Fungamyl has the advantage of being thermolabile and is inactivated just below the gelatinization temperature.
  • Enzyme preparations containing a number of pentosanase and hemi-cellulase activities can improve the handling and stabil ⁇ ity of the dough, and improves the freshness, the crumb structure and the volume of the bread.
  • Pentosanases can be used in combination with or as an alternative to emulsifiers.
  • carbohydrases are user for producing syrups from starch, which are widely used in soft drinks, sweets, meat products, dairy products, bread products, ice cream, baby food, jam etc.
  • the conversion of starch is normally carried out in three steps. First the starch is liquefied, by the use of ⁇ - amylases. Maltodextrins, primary consisting of oligosaccharides and dextrins, are obtained.
  • the mixture is then treated with an amyloglucosidase for hydrolysing the oligosaccharides and dextrins into glucose. This way a sweeter product is obtained. If high maltose syrups are desired ⁇ -amylases alone or in combination with a pullu- lanase (de-branching enzyme) may be used.
  • the glucose mixture can be made even sweeter by isomerization to fructose.
  • an immobilized glucose isomerase can be used for this an immobilized glucose isomerase.
  • dextranases are used to break down dextran in raw sugar juices and syrups.
  • ⁇ -amylases are advantageously being used for thinning of starch in distilling mashes.
  • ⁇ -galactosidases (lactase) are used when producing low lactose milk for persons suffering from lactose malabsorption.
  • flavoured milk drinks are produced from lactase-treated milk, the addition of sugar can be reduced without reducing the sweetness of the product.
  • lactose crystallization can be avoided by lactase treatment, and the risk of thickening caused by casein coagulation in lactose crystals is thus re ⁇ cuted.
  • xylanases are known to be used within a number of food/feed industrial applications as described in WO 94/21785 (Novo Nordisk A/S) .
  • ⁇ -amylases are used in the animal feed industry to be added to cereal-containing feed to improve the digestibility of starch.
  • Anti-microbial polypeptides are used in the animal feed industry to be added to cereal-containing feed to improve the digestibility of starch.
  • Certain bacteriolytic enzymes may be used e.g. to wash car ⁇ casses in the meat packing industry (see US patent no. 5,354,681 from Novo Industri A/S)
  • Transglutaminases with reduced allergenicity according to the invention may advantageously be used in the manufacturing of food and feed.
  • Transglutaminases have the ability to crosslinking protein.
  • This property can be used for gelling of aqueous phases con ⁇ taining proteins. This may be used for producing spreads (DK patent application no. 1071/84 from Novo Nordisk A/S) .
  • Transglutaminases are being used for improvement of baking quality of flour e.g. by modifying wheat flour to be used in the preparation of cakes with improved properties, such as improved taste, dent, mouth-feel and a higher volume (see JP 1- 110147) .
  • paste type food material e.g. used as fat substitution in foods as ice cream, toppings, frozen desserts, mayonnaise and low fat spreads (see WO 93/22930 from Novo Nordisk A/S) .
  • Phytases of the invention may advantageously be used in the manufacturing of food, such as breakfast cereal, cake, sweets, drink, bread or soup etc. , and animal feed. Phytases may be used either for exploiting the phosphorus bound in the phytate/phytic acid present in vegetable protein sources or for exploiting the nutritionally important minerals bound in phytic acid complexes.
  • Microbial phytase may be added to feedstuff of monogastric animals in order to avoid supplementing the feed with inorganic phosphorus (see US patent no. 3,297,548)
  • Soy bean meal may contain high levels of the anti-nutritional factor phytate which renders this protein source unsuitable for application in baby food and feed for fish, calves and other non-ruminants, since the phytate chelates essential minerals present therein (see EP 0 420 358) .
  • phytases may be used. Bread with better quality can be prepared by baking divided pieces of a dough containing wheat flour etc. and phytase (see JP-0-
  • a high phytase activity koji mold are known to be used for pro ⁇ ducing refined sake (see JP-0-6070749-A) .
  • Proteases are used for degumming and sand-washing of silk.
  • Lipases are used for removing fatty matter containing hydro ⁇ phobic esters (e.g. triglycerides) during the finishing of textiles (see e.g. WO 93/13256 from Novo Nordisk A/S) .
  • Oxidoreductases In bleach clean-up of textiles catalases may serve to remove excess hydrogen peroxide.
  • Cellulolytic enzymes are widely used in the finishing of denim garments in order to provide a localized variation in the co ⁇ lour density of the fabric (Enzyme facilitated "stone wash") .
  • Bio-Polishing is a specific treatment of the yarn surface which improves fabric quality with respect to handle and ap ⁇ pearance without loss of fabric wettability. Bio-polishing may be obtained by applying the method described e.g. in WO 93/20278.
  • the threads are exposed to con ⁇ siderable mechanical strain.
  • they are usually reinforced by coating (sizing) with a gelatinous substance (size) .
  • the most common sizing agent is starch in native or modified form. A uniform and durable finishing can thus be obtained only after removal of the size from the fa ⁇ bric, the so called desizing.
  • Desizing of fabrics sized with a size containing starch or modified starch is preferably facili ⁇ tated by use of amylolytic enzymes.
  • proteases Different combinations of highly purified proteases (e.g. Trypsin and Chy otrypsin) are used in pharmaceuticals to be taken orally, and dermal pharmaceuticals for combating e.g. inflammations, edemata and injuries.
  • highly purified proteases e.g. Trypsin and Chy otrypsin
  • Transglutaminase is known to be used for casein finishing of leather by acting as a hardening agent (see WO 94/13839 from Novo Nordisk) .
  • surfactant compositions in the form gels and foams comprising enzymes have shown to facilitate and improve hard surface cleaning.
  • Enzymes which advantageously may be added in such surfactant compositions, are in particular proteases, lipases, amylases and cellulases.
  • Such hard surface cleaning compositions comprising enzymes may also advantageously be used in the transport sector, for in ⁇ stance for washing cars and for general vessel wash.
  • the invention relates to the use of the conjugate of the invention or a composition of the invention in products comprising polypeptides.
  • conjugate or compositions of the invention can advantageously be used for personal care products, such as hair care and hair treatment products.
  • This include products such as shampoo, balsam, hair conditioners, hair waving compositions, hair dyeing compositions, hair tonic, hair liquid, hair cream, shampoo, hair rinse, hair spray.
  • oral care products such as dentifrice, mouth washes, chewing gum.
  • skin care products and cosmetics such as skin cream, skin milk, cleansing cream, cleansing lotion, cleansing milk, cold cream, cream soap, nourishing essence, skin lotion, milky lotion, calamine lotion, hand cream, powder soap, transparent soap, sun oil, sun screen, shaving foam, shaving cream, baby oil lipstick, lip cream, creamy foundation, face powder, powder eye-shadow, powder, foundation, make-up base, essence powder, whitening powder.
  • conjugate of the invention can be used advantageously.
  • Such products include contact lenses cleaning and disinfection products.
  • detergents such as washing powder, soap, soap bars, liquid soap are also contemplated.
  • Lipase Lipolase® (from Novo Nordisk A/S)
  • Cellulase Carezyme® core prepared as described according to Boisset, C. et al. (1995), FEBS Lett. 376, p. 49-52.
  • Dextran-peroxidase A (prepared by Kem-En-Tech, Denmark) .
  • Dextran-peroxidase B (prepared by Kem-En-Tech, Denmark) .
  • Dextran-cellulase (prepared by Kem-En-Tech, Denmark) .
  • Dextran-lipase (prepared by Kem-En-Tech, Denmark) .
  • the pH is adjusted to 9.0 with HCI, and Milli-Q water is applied to 1 litre.
  • the pH is adjusted to 10 with about 22.5 g KOH in Milli-Q water to 1 litre.
  • 50-100 ⁇ g enzyme protein is used per rabbit per injection.
  • Each rabbit is given an injection in the back of the neck (subcutaneous) with 1 ml fresh stable mix of 1:1 antigen and adjuvant.
  • ELISA procedure for determination of I G_ ⁇ positive guinea pigs ELISA microtiter plates are coated with rabbit anti-peroxidase 1:8000, rabbit anti-cellulase 1:8000 and anti-lipase 1:6000, respectively, in carbonate buffer and incubated over night at 4°C. The next day the plates are blocked with 2% BSA for 1 hour and washed 3 times with PBS tween 20.
  • Peroxidase, cellulase Core and lipase were added to the rele ⁇ vant plates, l ⁇ g enzyme protein/ml.
  • All guinea pig sera samples are applied to the ELISA plates with 10 ⁇ l sera and 90 ⁇ l PBS for peroxidase, and 1:50 dilu ⁇ tions of sera for cellulase and lipase, incubated for 1 hour and washed 3 times with PBS Tween20.
  • Alkaline phosphatase marked rabbit anti-goat 1:8000 is applied and incubated for 1 hour, washed 2 times in PBS Tween20 and 1 time with diethanol amine buffer.
  • the marked alkaline phophatase is developed using p-nitrophenyl phosphate for 30 minutes at 37°C and stopped with calci ⁇ um/sodium buffer comprising EDTA (pH 10) and read at OD 405/650 using a ELISA reader.
  • Double blinds are included on all ELISA plates.
  • Figure 1 shows the number of Dunkin Hartley guinea pigs found IgGi positive during the trail period.
  • the modified lipase has a reduced allergenicity.
  • Example 2 The trails described in Example 1 were repeated, except that the Dunkin Hartley guinea pigs were stimulated intratracheally with either 1 ⁇ g purified cellulase or 1 ⁇ g purified modified cellulase.
  • the modified lipase has a reduced allergenicity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Immunology (AREA)
  • Detergent Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Cosmetics (AREA)

Abstract

L'invention porte sur des conjugués de polypeptides à allergénicité réduite comportant une molécule support polymérique à laquelle son fixées deux ou plus de deux molécules de polypeptides. L'invention porte également sur un procédé de production desdits conjugués, sur des compositions les contenant, et sur leur utilisation dans un grand nombre d'applications industrielles telles que des produits pour soins personnel et des détergents.
PCT/DK1997/000051 1996-02-15 1997-02-07 Conjugaison de polypeptides WO1997030148A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP97901524A EP0894128A1 (fr) 1996-02-15 1997-02-07 Conjugaison de polypeptides
JP9528900A JP2000506119A (ja) 1996-02-15 1997-02-07 ポリペプチドのコンジュゲーション
AU15406/97A AU725287B2 (en) 1996-02-15 1997-02-07 Conjugation of polypeptides
US09/123,787 US6106828A (en) 1996-02-15 1998-07-28 Conjugation of polypeptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK15496 1996-02-15
DK0154/96 1996-02-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/123,787 Continuation US6106828A (en) 1996-02-15 1998-07-28 Conjugation of polypeptides

Publications (1)

Publication Number Publication Date
WO1997030148A1 true WO1997030148A1 (fr) 1997-08-21

Family

ID=8090373

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1997/000051 WO1997030148A1 (fr) 1996-02-15 1997-02-07 Conjugaison de polypeptides

Country Status (6)

Country Link
EP (1) EP0894128A1 (fr)
JP (1) JP2000506119A (fr)
CN (1) CN1273589C (fr)
AU (1) AU725287B2 (fr)
CA (1) CA2242488A1 (fr)
WO (1) WO1997030148A1 (fr)

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030682A1 (fr) * 1997-01-10 1998-07-16 Novo Nordisk A/S Enzyme couplee a des molecules polymeres pour les soins de la peau
WO1999057252A1 (fr) * 1998-05-01 1999-11-11 The Procter & Gamble Company Compositions de detergent a lessive et/ou d'entretien de tissus contenant une enzyme modifiee
WO1999067370A1 (fr) * 1998-06-23 1999-12-29 Novozymes A/S Conjugue polypeptide-polymere
WO2000004138A1 (fr) * 1998-07-17 2000-01-27 Novozymes A/S Conjugue polypeptide-polymeres a efficacite de lavage amelioree
WO1999053038A3 (fr) * 1998-04-15 2000-02-10 Genencor Int Proteines mutantes avec une reponse allergene plus faible chez l'homme et methodes pour construire, identifier, et produire ces proteines
WO2000022103A1 (fr) * 1998-10-13 2000-04-20 Novozymes A/S Polypeptide modifie a reponse immunitaire reduite
WO2001064176A1 (fr) * 2000-03-01 2001-09-07 Henkel Kommanditgesellschaft Auf Aktien Gel nettoyant pour la peau a effet chauffant
DE10047481A1 (de) * 2000-09-26 2002-04-25 Henkel Kgaa Wasch- und Reinigungsmittel
US6416756B1 (en) 1997-01-10 2002-07-09 Novozymes A/S Modified protease having 5 to 13 covalently coupled polymeric molecules for skin care
EP1234584A1 (fr) * 2001-02-21 2002-08-28 Grisotech S.A. Complexes d'immunoglobulines et polysaccharides absorption orale ou transmucosale
WO2002077187A2 (fr) 2001-03-23 2002-10-03 Genencor International, Inc. Proteines provoquant une reaction immunogene modifiee, et methodes de production et d'utilisation desdites proteines
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6468955B1 (en) 1998-05-01 2002-10-22 The Proctor & Gamble Company Laundry detergent and/or fabric care compositions comprising a modified enzyme
US6495136B1 (en) 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
US6566115B1 (en) 1999-07-22 2003-05-20 The Procter & Gamble Company Protease conjugates having sterically protected clip sites
US6569663B1 (en) 1998-03-26 2003-05-27 The Procter & Gamble Company Serine protease variants having amino acid substitutions
US6586224B1 (en) 1999-07-22 2003-07-01 The Procter & Gamble Company Subtilisin protease variants having amino acid deletions and substitutions in defined epitope regions
US6586223B1 (en) 1999-07-22 2003-07-01 The Procter & Gamble Company Subtilisin protease variants having amino acid substitutions in defined epitope regions
US6638526B1 (en) 1998-06-23 2003-10-28 Novozymes A/S Polypeptides conjugated to copolymers of ethylene oxide and propylene oxide to reduce allergenicity
US6642011B2 (en) 1998-04-15 2003-11-04 Genencor International, Inc. Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
WO2003099243A1 (fr) * 2002-05-29 2003-12-04 Henkel Kommanditgesellschaft Auf Aktien Agents cosmetiques comprenant une disulfidisomerase proteinique
DE10227238A1 (de) * 2002-06-19 2004-01-15 Wella Ag Hochaffine kosmetische Mittel
WO2004030701A1 (fr) * 2002-09-11 2004-04-15 Fresenius Kabi Deutschland Gmbh Conjugue amidon hydroxyalkyle-allergene
US6838269B1 (en) 1998-04-15 2005-01-04 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6897049B1 (en) 1998-04-15 2005-05-24 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
US6951939B2 (en) 2000-06-08 2005-10-04 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
JP2005535652A (ja) * 2002-07-09 2005-11-24 サンド・アクチエンゲゼルシヤフト １，２−プロピレングリコールを含有するヒト成長ホルモン（ｈＧＨ）の高濃度液体製剤
WO2005077319A3 (fr) * 2004-02-12 2006-08-24 Unilever Plc Compositions de traitement capillaire
WO2006050691A3 (fr) * 2004-11-02 2006-09-21 Imasys Ag Dispositif de pose, dispositif d'etablissement de contact, systeme d'avance, unite de pose et d'etablissement de contact, installation de production, procede de production et ensemble transpondeur
US7115581B2 (en) 1992-07-15 2006-10-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US7332320B2 (en) 2001-12-31 2008-02-19 Genencor International, Inc. Protease producing an altered immunogenic response and methods of making and using the same
WO2007123271A3 (fr) * 2006-04-21 2008-02-21 Kao Corp Composition d'agent de lutte contre un biofilm
US7538092B2 (en) 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US7541328B2 (en) 2002-03-06 2009-06-02 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide
DE202008017456U1 (de) 2007-08-27 2009-08-27 Biogenerix Ag Flüssig-Formulierung von G-CSF-Konjugaten
US7632669B2 (en) 1998-11-27 2009-12-15 Novozymes A/S Lipolytic enzyme variants
EP2113563A3 (fr) * 1998-11-27 2010-01-13 Novozymes A/S Variants d'enzyme lipolytique
EP2270036A2 (fr) 2004-03-11 2011-01-05 Fresenius Kabi Deutschland GmbH Polypeptides hasylés
WO2014067933A1 (fr) * 2012-10-31 2014-05-08 C-Lecta Gmbh Préparation de support bioactif pour une sécurité améliorée dans les produits de soin et les aliments
CN104125838A (zh) * 2011-12-20 2014-10-29 辉瑞公司 制备肽缀合物和连接基的改进方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8021436B2 (en) * 2007-09-27 2011-09-20 The Procter & Gamble Company Cleaning and/or treatment compositions comprising a xyloglucan conjugate
EP2070950A1 (fr) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Dérivés hydroxyalkylés de l'amidon et leur procédé de préparation

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0183503A2 (fr) * 1984-11-30 1986-06-04 Beecham Group Plc Conjugués de protéines d'utilité pharmaceutique
EP0223221A2 (fr) * 1985-11-21 1987-05-27 Roche Diagnostics GmbH Dérivé stabilisé et soluble dans l'eau de la peroxydase, son procédé de préparation et utilisation pour la détermination du peroxyde d'hydrogène
US5006333A (en) * 1987-08-03 1991-04-09 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5133968A (en) * 1990-08-20 1992-07-28 Kanebo, Ltd. Modified protease, method of producing the same and cosmetic products containing the modified protease
US5230891A (en) * 1990-08-20 1993-07-27 Kanebo Limited Modified protease, method of producing the same and cosmetic products containing the modified protease
WO1996017929A1 (fr) * 1994-12-07 1996-06-13 Novo Nordisk A/S Polypeptide a allergenicite reduite
WO1996040791A1 (fr) * 1995-06-07 1996-12-19 Novo Nordisk A/S Modification de polypeptides

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
EP0183503A2 (fr) * 1984-11-30 1986-06-04 Beecham Group Plc Conjugués de protéines d'utilité pharmaceutique
EP0223221A2 (fr) * 1985-11-21 1987-05-27 Roche Diagnostics GmbH Dérivé stabilisé et soluble dans l'eau de la peroxydase, son procédé de préparation et utilisation pour la détermination du peroxyde d'hydrogène
US5006333A (en) * 1987-08-03 1991-04-09 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5133968A (en) * 1990-08-20 1992-07-28 Kanebo, Ltd. Modified protease, method of producing the same and cosmetic products containing the modified protease
US5230891A (en) * 1990-08-20 1993-07-27 Kanebo Limited Modified protease, method of producing the same and cosmetic products containing the modified protease
WO1996017929A1 (fr) * 1994-12-07 1996-06-13 Novo Nordisk A/S Polypeptide a allergenicite reduite
WO1996040791A1 (fr) * 1995-06-07 1996-12-19 Novo Nordisk A/S Modification de polypeptides

Cited By (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351855B2 (en) 1992-07-15 2008-04-01 La Jolla Pharmaceutical Company Chemically defined non-polymeric valency platform molecules and conjugates thereof
US7115581B2 (en) 1992-07-15 2006-10-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US6416756B1 (en) 1997-01-10 2002-07-09 Novozymes A/S Modified protease having 5 to 13 covalently coupled polymeric molecules for skin care
WO1998030682A1 (fr) * 1997-01-10 1998-07-16 Novo Nordisk A/S Enzyme couplee a des molecules polymeres pour les soins de la peau
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
US6569663B1 (en) 1998-03-26 2003-05-27 The Procter & Gamble Company Serine protease variants having amino acid substitutions
US6495136B1 (en) 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
US6897049B1 (en) 1998-04-15 2005-05-24 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6838269B1 (en) 1998-04-15 2005-01-04 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6936249B1 (en) 1998-04-15 2005-08-30 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6642011B2 (en) 1998-04-15 2003-11-04 Genencor International, Inc. Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
US6835550B1 (en) 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US6596525B1 (en) 1998-04-15 2003-07-22 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
WO1999053038A3 (fr) * 1998-04-15 2000-02-10 Genencor Int Proteines mutantes avec une reponse allergene plus faible chez l'homme et methodes pour construire, identifier, et produire ces proteines
EP1997897A1 (fr) 1998-04-15 2008-12-03 Genencor International, Inc. Protéines mutantes disposant d'une réponse allergénique inférieure chez les humains et procédés de construction, d'identification et de production de telles protéines
WO1999057252A1 (fr) * 1998-05-01 1999-11-11 The Procter & Gamble Company Compositions de detergent a lessive et/ou d'entretien de tissus contenant une enzyme modifiee
WO1999057250A1 (fr) * 1998-05-01 1999-11-11 The Procter & Gamble Company Detergent de lavage et/ou compositions respectant les tissus comprenant une enzyme modifiee
US6468955B1 (en) 1998-05-01 2002-10-22 The Proctor & Gamble Company Laundry detergent and/or fabric care compositions comprising a modified enzyme
US6638526B1 (en) 1998-06-23 2003-10-28 Novozymes A/S Polypeptides conjugated to copolymers of ethylene oxide and propylene oxide to reduce allergenicity
WO1999067370A1 (fr) * 1998-06-23 1999-12-29 Novozymes A/S Conjugue polypeptide-polymere
WO2000004138A1 (fr) * 1998-07-17 2000-01-27 Novozymes A/S Conjugue polypeptide-polymeres a efficacite de lavage amelioree
WO2000022103A1 (fr) * 1998-10-13 2000-04-20 Novozymes A/S Polypeptide modifie a reponse immunitaire reduite
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US7632669B2 (en) 1998-11-27 2009-12-15 Novozymes A/S Lipolytic enzyme variants
EP2113563A3 (fr) * 1998-11-27 2010-01-13 Novozymes A/S Variants d'enzyme lipolytique
US7851176B2 (en) 1998-11-27 2010-12-14 Novozymes A/S Lipolytic enzyme variants
US8679774B2 (en) 1998-11-27 2014-03-25 Novozymes A/S Lipolytic enzyme variants
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
US6586224B1 (en) 1999-07-22 2003-07-01 The Procter & Gamble Company Subtilisin protease variants having amino acid deletions and substitutions in defined epitope regions
US6566115B1 (en) 1999-07-22 2003-05-20 The Procter & Gamble Company Protease conjugates having sterically protected clip sites
US6586223B1 (en) 1999-07-22 2003-07-01 The Procter & Gamble Company Subtilisin protease variants having amino acid substitutions in defined epitope regions
WO2001064176A1 (fr) * 2000-03-01 2001-09-07 Henkel Kommanditgesellschaft Auf Aktien Gel nettoyant pour la peau a effet chauffant
US6641825B2 (en) 2000-03-01 2003-11-04 Henkel Kommanditgesellschaft Auf Aktien Skin cleansing gel having a heating effect
US6951939B2 (en) 2000-06-08 2005-10-04 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
DE10047481A1 (de) * 2000-09-26 2002-04-25 Henkel Kgaa Wasch- und Reinigungsmittel
US6913746B2 (en) 2001-02-21 2005-07-05 Grisotech S.A. Complexes of immunoglobulins polysaccharides for oral and transmucosal absorption
EP1234584A1 (fr) * 2001-02-21 2002-08-28 Grisotech S.A. Complexes d'immunoglobulines et polysaccharides absorption orale ou transmucosale
WO2002077187A2 (fr) 2001-03-23 2002-10-03 Genencor International, Inc. Proteines provoquant une reaction immunogene modifiee, et methodes de production et d'utilisation desdites proteines
US7476528B2 (en) 2001-03-23 2009-01-13 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6929939B2 (en) 2001-03-23 2005-08-16 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US7332320B2 (en) 2001-12-31 2008-02-19 Genencor International, Inc. Protease producing an altered immunogenic response and methods of making and using the same
US7541328B2 (en) 2002-03-06 2009-06-02 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide
US8916518B2 (en) 2002-03-06 2014-12-23 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide
WO2003099243A1 (fr) * 2002-05-29 2003-12-04 Henkel Kommanditgesellschaft Auf Aktien Agents cosmetiques comprenant une disulfidisomerase proteinique
WO2003099242A1 (fr) * 2002-05-29 2003-12-04 Henkel Kommanditgesellschaft Auf Aktien Agents cosmetiques comprenant une disulfidisomerase proteinique
DE10227238A1 (de) * 2002-06-19 2004-01-15 Wella Ag Hochaffine kosmetische Mittel
JP2005535652A (ja) * 2002-07-09 2005-11-24 サンド・アクチエンゲゼルシヤフト １，２−プロピレングリコールを含有するヒト成長ホルモン（ｈＧＨ）の高濃度液体製剤
WO2004030701A1 (fr) * 2002-09-11 2004-04-15 Fresenius Kabi Deutschland Gmbh Conjugue amidon hydroxyalkyle-allergene
RU2325925C2 (ru) * 2002-09-11 2008-06-10 Фрезениус Каби Дойчланд Гмбх Конъюгаты гидроксиалкилкрахмала и аллергена
US7538092B2 (en) 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
WO2005077319A3 (fr) * 2004-02-12 2006-08-24 Unilever Plc Compositions de traitement capillaire
EP2270036A2 (fr) 2004-03-11 2011-01-05 Fresenius Kabi Deutschland GmbH Polypeptides hasylés
EP2270037A2 (fr) 2004-03-11 2011-01-05 Fresenius Kabi Deutschland GmbH Facteur IX hasylés
US8840879B2 (en) 2004-03-11 2014-09-23 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
WO2006050691A3 (fr) * 2004-11-02 2006-09-21 Imasys Ag Dispositif de pose, dispositif d'etablissement de contact, systeme d'avance, unite de pose et d'etablissement de contact, installation de production, procede de production et ensemble transpondeur
WO2007123271A3 (fr) * 2006-04-21 2008-02-21 Kao Corp Composition d'agent de lutte contre un biofilm
EP2578235A2 (fr) 2007-08-27 2013-04-10 BioGeneriX AG Formulation liquide de conjugué de G-CSF
DE202008017456U1 (de) 2007-08-27 2009-08-27 Biogenerix Ag Flüssig-Formulierung von G-CSF-Konjugaten
CN104125838A (zh) * 2011-12-20 2014-10-29 辉瑞公司 制备肽缀合物和连接基的改进方法
WO2014067933A1 (fr) * 2012-10-31 2014-05-08 C-Lecta Gmbh Préparation de support bioactif pour une sécurité améliorée dans les produits de soin et les aliments

Also Published As

Publication number Publication date
AU725287B2 (en) 2000-10-12
CN1211278A (zh) 1999-03-17
JP2000506119A (ja) 2000-05-23
CN1273589C (zh) 2006-09-06
EP0894128A1 (fr) 1999-02-03
AU1540697A (en) 1997-09-02
CA2242488A1 (fr) 1997-08-21

Similar Documents

Publication Publication Date Title
AU725287B2 (en) Conjugation of polypeptides
US6106828A (en) Conjugation of polypeptides
US6303752B1 (en) Polypeptides conjugated with polymers
WO1996040791A1 (fr) Modification de polypeptides
AU697440B2 (en) Polypeptide with reduced allergenicity
AU736806B2 (en) A modified enzyme for skin care
ES2220114T3 (es) Variantes de proteinas poco alergenicas.
ES2289824T3 (es) Proteinas glicosiladas con alergenicidad reducida.
AU768765B2 (en) A polypeptide-polymer conjugate
US6416756B1 (en) Modified protease having 5 to 13 covalently coupled polymeric molecules for skin care
US6638526B1 (en) Polypeptides conjugated to copolymers of ethylene oxide and propylene oxide to reduce allergenicity
AU731076B2 (en) Composition comprising polypeptide with reduced allergenicity

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97192294.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2242488

Country of ref document: CA

Ref document number: 2242488

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1997901524

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09123787

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997901524

Country of ref document: EP